1. Brines M, Dunne AN, van Velzen M,et al. (2014) ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2014; 20: 658-666.
  2. Brines M, Patel NS, Villa P, et al. (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008; 105: 10925-10930.
  3. Collino M, Benetti E, Rogazzo M, et al. (2014) A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol. 2014; 171: 5802-5815.
  4. Collino M, Thiemermann C, Cerami A, Brines M. (2015) Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. 2015; 151: 32-40.
  5. Dahan A, Dunne A, Swartjes M, et al. (2013) ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013; 19: 334-345.
  6. McVicar CM, Hamilton R, Colhoun LM, et al. (2011) intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes 2011; 60: 2995-3005.
  7. Patel NS, Kerr-Peterson HL, Brines M, et al. (2012) Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med. 2012; 18: 719-727.
  8. Pulman KG, Smith M, Mengozzi M, Ghezzi P, Dilley A. (2013) The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. Neuroscience. 2013; 233: 174-183.
  9. Schmidt RE, Feng D, Wang Q, et al. (2011) Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol. 2011; 232: 126-135.
  10. Swartjes M, Morariu A, Niesters M, et al. (2011) ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology. 2011; 115: 1084-1092.
  11. Swartjes M, van Velzen M, Niesters M, et al. (2014) ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014; 10: 13.
  12. Watanabe M, Lundgren T, Saito Y, et al (2015) A nonhematopoietic erythropoietin analogue, ARA 290, inhibits macrophage activation and prevents damage to transplanted islets. Transplantation. 2015;100:554-562.